EUROAPI Logo
FR0014008VX5

EUROAPI

Ins Portfolio
Kostengünstig und breit gestreut in Europa investieren. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Kaufen
  0
Halten
  0
Verkaufen
  1

Scoring-Modelle

Dividenden-Strategie0 / 15
HGI-Strategie6 / 18
Levermann-Strategie2 / 13
Powered byaktien.guide

News


  • EUROAPI sells Haverhill site to Particle Dynamics as part of its FOCUS-27 transformation plan

    Paris – June 30, 2025 – EUROAPI today announced the signing of a share purchase agreement (SPA) for the sale of 100% of EUROAPI UK Ltd, the subsidiary operating its Haverhill manufacturing site, with a simultaneous closing to Particle Dynamics - a global leader in particle processing, delivery technologies, and finished dose manufacturing for the nutraceutical, consumer health, and pharmaceutical sectors.» Mehr auf globenewswire.com


  • Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities

    Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce the appointment of Frédéric Robert to the newly created position of Chief Commercial Officer overseeing API Solutions and CDMO activities. He will join the company's Executive Committee. This appointment is part of EUROAPI's ongoing FOCUS-27 transformation plan and reinforces its position as a European leader in the API and CDMO sectors.» Mehr auf globenewswire.com


  • EUROAPI moves into a new chapter with new Governance and Leadership

    Paris – December 9, 2024 – With FOCUS-27 strategic plan foundations established and its financing secured, EUROAPI moves into a new chapter. The company's Board of Directors has accepted today the resignation of Viviane Monges as Director and Chair of the Board and Ludwig de Mot as Chief Executive Officer. Consequently, upon the recommendation of the Nominations and Compensation Committee, the Board has appointed Emmanuel Blin as Chair of the Board and David Seignolle as Chief Executive Officer, effective immediately. In response to the new governance, Elizabeth Bastoni stepped down as Independent Lead Director; she remains Chair of the Nominations and Compensation Committee. » Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte EUROAPI einen Umsatz von +468,30 Mio und ein Nettoeinkommen von 95,80 Mio
(EUR)Dez. 2024
YOY
Umsatz+468,30 Mio-
Bruttoeinkommen+44,40 Mio-
Nettoeinkommen95,80 Mio-
EBITDA77,40 Mio-

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+305,37 Mio
Anzahl Aktien
95,23 Mio
52 Wochen-Hoch/Tief
+3,39 - +2,11
DividendenNein
Beta
0,69
KGV (PE Ratio)
2,36
KGWV (PEG Ratio)
0,04
KBV (PB Ratio)
+0,31
KUV (PS Ratio)
+0,34

Unternehmensprofil

Euroapi SA entwickelt, produziert, vermarktet und vertreibt pharmazeutische Wirkstoffe und Zwischenprodukte für die Formulierung von Human- und Tierarzneimitteln. Das Unternehmen wurde im Jahr 2021 gegründet und hat seinen Sitz in Paris, Frankreich.

Name
EUROAPI
CEO
David Seignolle
SitzParis,
Frankreich
Website
Börsengang
Mitarbeiter3.187

Ticker Symbole

BörseSymbol
Euronext
EAPI.PA
Pnk
EAPIF
Frankfurt
940.F
Düsseldorf
940.DU
London
0EAP.L
Paris
EAPI.PA
München
940.MU

Assets entdecken

Shareholder von EUROAPI investieren auch in folgende Assets

🍪

Parqet nutzt Cookies.Erfahre Mehr